• Something wrong with this record ?

Inhibition of human serine racemase, an emerging target for medicinal chemistry

J. Jirásková-Vaníčková, R. Ettrich, B. Vorlová, HE. Hoffman, M. Lepšík, P. Jansa, J. Konvalinka,

. 2011 ; 12 (7) : 1037-55.

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after. The opening of the NMDA receptor ion channel requires occupation of two distinct binding sites, the glutamate site and the glycine site. It has been shown that D-serine, rather than glycine, can trigger the physiological NMDA receptor function. D-serine is a product of the activity of a specific enzyme, serine racemase (SR), which was identified a decade ago. SR has therefore emerged as a new potential target for the NMDA-receptor-based diseases. There is evidence linking increased levels of D-Ser to amyotrophic lateral sclerosis and Alzheimer's disease and decreased concentrations of D-serine to schizophrenia. SR is a pyridoxal-5'-phosphate dependent enzyme found in the cytosol of glial and neuronal cells. It is activated by ATP, divalent cations like Mg(2+) or Ca(2+), and reducing agents. This paper reviews the present literature on the activity and inhibition of mammalian SRs. It summarizes approaches that have been applied to design SR inhibitors and lists the known active compounds. Based on biochemical and docking analyses, i) we delineate for the first time the ATP binding site of human SR, and ii) we suggest possible mechanisms of action for the active compounds. In the end, we discuss the SR features that make the discovery of its inhibitors a challenging, yet very important, task of medicinal chemistry.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027841
003      
CZ-PrNML
005      
20121207092935.0
007      
ta
008      
120817s2011 ne f 000 0#eng||
009      
AR
024    7_
$a 10.2174/138945011795677755 $2 doi
035    __
$a (PubMed)21291385
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Jirásková, Jana $7 xx0102285 $u Gilead Sciences and IOCB Research Center Prague, Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
245    10
$a Inhibition of human serine racemase, an emerging target for medicinal chemistry / $c J. Jirásková-Vaníčková, R. Ettrich, B. Vorlová, HE. Hoffman, M. Lepšík, P. Jansa, J. Konvalinka,
520    9_
$a Proteins of glutamatergic NMDA receptor signaling pathways have been studied as targets for intervention in a variety of neuropathological conditions, including neurodegenerations, epilepsy, neuropathic pain, drug addiction, and schizophrenia. High activity NMDA-blocking agents have been designed to treat some of these disorders; however, their effect is often compromised by undesirable side effects. Therefore, alternative ways of modulating NMDA receptor function need to be sought after. The opening of the NMDA receptor ion channel requires occupation of two distinct binding sites, the glutamate site and the glycine site. It has been shown that D-serine, rather than glycine, can trigger the physiological NMDA receptor function. D-serine is a product of the activity of a specific enzyme, serine racemase (SR), which was identified a decade ago. SR has therefore emerged as a new potential target for the NMDA-receptor-based diseases. There is evidence linking increased levels of D-Ser to amyotrophic lateral sclerosis and Alzheimer's disease and decreased concentrations of D-serine to schizophrenia. SR is a pyridoxal-5'-phosphate dependent enzyme found in the cytosol of glial and neuronal cells. It is activated by ATP, divalent cations like Mg(2+) or Ca(2+), and reducing agents. This paper reviews the present literature on the activity and inhibition of mammalian SRs. It summarizes approaches that have been applied to design SR inhibitors and lists the known active compounds. Based on biochemical and docking analyses, i) we delineate for the first time the ATP binding site of human SR, and ii) we suggest possible mechanisms of action for the active compounds. In the end, we discuss the SR features that make the discovery of its inhibitors a challenging, yet very important, task of medicinal chemistry.
650    _2
$a adenosintrifosfát $x metabolismus $7 D000255
650    _2
$a zvířata $7 D000818
650    _2
$a vazebná místa $7 D001665
650    _2
$a lékové transportní systémy $7 D016503
650    _2
$a racionální návrh léčiv $7 D015195
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a lidé $7 D006801
650    _2
$a nemoci nervového systému $x farmakoterapie $x patofyziologie $7 D009422
650    _2
$a racemasy a epimerasy $x antagonisté a inhibitory $x metabolismus $7 D019998
650    _2
$a receptory N-methyl-D-aspartátu $x účinky léků $x metabolismus $7 D016194
650    _2
$a serin $x metabolismus $7 D012694
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Ettrich, Rudiger
700    1_
$a Vorlová, Barbora
700    1_
$a Hoffman, Hillary E
700    1_
$a Lepšík, Martin
700    1_
$a Jansa, Petr
700    1_
$a Konvalinka, Jan
773    0_
$w MED00007902 $t Current drug targets $x 1873-5592 $g Roč. 12, č. 7 (2011), s. 1037-55
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21291385 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m
990    __
$a 20120817 $b ABA008
991    __
$a 20121207093009 $b ABA008
999    __
$a ok $b bmc $g 949883 $s 785187
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 12 $c 7 $d 1037-55 $i 1873-5592 $m Current drug targets $n Curr Drug Targets $x MED00007902
LZP    __
$a Pubmed-20120817/11/03

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...